Results 251 to 260 of about 366,991 (303)

Liposomal cisplatin: a new cisplatin formulation

Anti-Cancer Drugs, 2010
Over the last three decades, cisplatin has been one of the most effective cytotoxic agents, but its administration has been hindered by its nephrotoxicity, neurotoxicity and myelo toxicity. Recently, liposomal cisplatin, lipoplatin, has been formulated and tested thoroughly in preclinical (in vitro) and phase I, II and III trials, as documented in the ...
openaire   +2 more sources

Cisplatin

Reactions Weekly, 2022
  +7 more sources

Cisplatin Neuropathy

Neurology, 1995
Hol, EM, Bar, PR, Cavaletti, G, Tredici, G, Windebank, AJ, Gordon, SA, Russell, JW   +6 more
openaire   +1 more source

Pembrolizumab in combination with gemcitabine and cisplatin compared with gemcitabine and cisplatin alone for patients with advanced biliary tract cancer (KEYNOTE-966): a randomised, double-blind, placebo-controlled, phase 3 trial

Lancet, The, 2023
Makoto Ueno, Heinz-Josef Klümpen, Mohamed bouattour   +2 more
exaly  

Cisplatin see Epirubicin/cisplatin

Reactions Weekly, 1990
openaire   +1 more source

Cisplatin see Fluorouracil + cisplatin

Reactions Weekly, 1991
openaire   +1 more source

Cisplatin overdosage.

Journal of Clinical Oncology, 1992
I M, Pike, M H, Arbus
openaire   +4 more sources

Cisplatin ototoxicity

Indian Journal of Cancer, 2009
openaire   +2 more sources

Cisplatin

Reactions Weekly, 2023
  +4 more sources

Cisplatin see Carboplatin/cisplatin

Reactions Weekly, 1990
openaire   +1 more source